Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Paroxysmal Nocturnal Hemoglobinuria

Hematology

Hematology Today—March 16, 2026

This week’s Hematology update highlights regulatory filings, positive…

Rare Disease news

Rare Disease Today—January 8, 2026

This rare disease update covers major regulatory approvals, strategic…

Artificial_Intelligence

AI in Healthcare and Digital Health Today—December 15, 2025

This AI in Healthcare and Digital Health update highlights the biggest…

Hematology

Latest Hematology News - Sept 22nd to Oct 6th 2025

Watch Our Video Summary Capturing Top Hematology News from the Last Two Weeks…

EHA 2025_Preview_by_LucidQuest

EHA 2025 Preview: Key Hematology Highlights to Watch

EHA at a glance Join LucidQuest for a concise EHA 2025 preview, focusing on…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Oncology Today—March 23, 2026

Tags

acute care ANKTIVA Autoimmune pulmonary alveolar proteinosis Behcet’s disease Bivamelagon Cardiac Rehab Cardiovascular Risk chronic disease prevention Cinainu Clostridioides Difficile Competitive Intelligence Process Duchenne MD ESC2025 Exosome Vaccines GLP1 drugs Halozyme healthcare tech Hypothalamic obesity treatment IgG4 Related Disease Kobe University KRAS luspatercept Macular degeneration Mantle Cell Lymphoma med tech Metformin Microplastics MOLBREEVI Nutrition Science Osteoporosis drug development pediatric rare disease pouchitis Priovant Therapeutics QTORIN rapamycin Recordati robotic surgery RRMS Segmed Sjögrens Disease Speech Biomarkers SylamoreBio Symplicity Spyral Ultrahuman Ring Air Undifferentiated Pleomorphic Sarcoma Vaxxas

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Oncology Today—March 23, 2026

TAGS

acute care ANKTIVA Autoimmune pulmonary alveolar proteinosis Behcet’s disease Bivamelagon Cardiac Rehab Cardiovascular Risk chronic disease prevention Cinainu Clostridioides Difficile Competitive Intelligence Process Duchenne MD ESC2025 Exosome Vaccines GLP1 drugs Halozyme healthcare tech Hypothalamic obesity treatment IgG4 Related Disease Kobe University KRAS luspatercept Macular degeneration Mantle Cell Lymphoma med tech Metformin Microplastics MOLBREEVI Nutrition Science Osteoporosis drug development pediatric rare disease pouchitis Priovant Therapeutics QTORIN rapamycin Recordati robotic surgery RRMS Segmed Sjögrens Disease Speech Biomarkers SylamoreBio Symplicity Spyral Ultrahuman Ring Air Undifferentiated Pleomorphic Sarcoma Vaxxas

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy